WilliamJSandbornMD

PubMed

• Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE...
  Geert D'Haens, Filip Baert, Silvio Danese, Taku Kobayashi, Edward V Loftus Jr, William J Sandborn, Quentin Dornic, Dirk Lindner, Krisztina Kisfalvi, Ed G Marins, Séver...> ;European Journal of Gastroenterology & Hepatology. 2024 Apr 1
• Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis.
  Geert D'Haens, Maria Rosario, Daniel Polhamus, Nathanael L Dirks, Chunlin Chen, Krisztina Kisfalvi, Christian Agboton, Séverine Vermeire, Brian G Feagan, William J San...> ;Expert Review of Clinical Pharmacology. 2024 Mar 5
• Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT tr...
  Jairath, V., Zou, G., Wang, Z., Adsul, S., Colombel, J., D'Haens, G., Freire, M., Moran, G., Peyrin-Biroulet, L., Sandborn, W., Sebastian, S., Travis, S., Vermeire, S....> ;BMJ Open Gastroenterology. 2024 Feb 8
• Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis.
  Ghosh, S., Feagan, B., Ott, E., Gasink, C., Godwin, B., Marano, C., Miao, Y., Ma, T., Loftus, E., Danese, S., Abreu, M., Sandborn, W., Sands, B.> ;Journal of Crohn's & Colitis. 2024 Feb 4
• Clinical Trial Design in Ulcerative Colitis: Interpreting Evolving Endpoints Based on Post Hoc Analyses of the Vedolizumab Phase 3 Trials GEMINI 1 and VISIBLE 1.
  Uddin, S., Qasim Khan, R., Sagar Mukherjee, R., Sandborn, W., Sands, B.> ;Crohn's & Colitis 360. 2024 Jan 1
• Pangenome comparison ofgenomospecies unveil genetic diversity and ecological insights.
  Oles, R., Terrazas, M., Loomis, L., Hsu, C., Tribelhorn, C., Ferre, P., Ea, A., Bryant, M., Carrow, H., Pride, D., Knight, R., Chu, H., Young, J., Sandborn, W., Dulai,...> ;Biorxiv. 2023 Dec 21
• 2 citations
  Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study.
  Afif, W., Arasaradnam, R., Danese, S., Miao, Y., Zhang, H., Panaccione, R., Hisamatsu, T., Leong, R., Rowbotham, D., Peyrin-Biroulet, L., Marano, C., Abreu, M., Sandbo...> ;The American Journal of Gastroenterology. 2024 Jan 26
• 1 citations
  Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
  Danese, S., Panaccione, R., Feagan, B., Afzali, A., Rubin, D., Sands, B., Reinisch, W., Panés, J., Sahoo, A., Terry, N., Chan, D., Han, C., Frustaci, M., Yang, Z., San...> ;The Lancet. Gastroenterology & Hepatology. 2024 Feb 1
• Efficacy and Safety of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease.
  Vermeire, S., Danese, S., Schreiber, S., D'Haens, G., Nagy, P., Thakur, M., Bliss, C., Cataldi, F., Goetsch, M., Gorelick, K., Reinisch, W., Sandborn, W., Hanauer, S.> ;Journal of Crohn's & Colitis. 2023 Dec 14
• Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies.
  William J Sandborn, Jingjing Chen, Krisztina Kisfalvi, Edward V Loftus Jr, Geert D'Haens, Ninfa Candela, Karen Lasch, Douglas C Wolf, Sharif M Uddin, Silvio Danese> ;Crohn's & Colitis 360. 2023 Jul 1
• 10 citations
  Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
  Geert D'Haens, Marla Dubinsky, Taku Kobayashi, Peter M Irving, Stefanie Howaldt, Juris Pokrotnieks, Kathryn Krueger, Janelle Laskowski, Xingyuan Li, Trevor Lissoos, Jo...> ;The New England Journal of Medicine. 2023 Jun 29
• Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease.
  Jean-Frédéric Colombel, Bruce E Sands, Christopher Gasink, Benjamin Yeager, Omoniyi J Adedokun, James Izanec, Tony Ma, Long-Long Gao, Scott D Lee, Stephan R Targan, Su...> ;Clinical Gastroenterology and Hepatology. 2024 Jan 1
• 1 citations
  A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis.
  Geert D'Haens, Laurent Peyrin-Biroulet, Daniel J B Marks, Edoardo Lisi, Lia Liefaard, Andrew Beaton, Naren Srinivasan, Gerben Bouma, Naveen Prasad, Raymond Cameron, Ze...> ;Alimentary Pharmacology & Therapeutics. 2023 Aug 1
• 1 citations
  Standardizing Scoring Conventions for Crohn's Disease Endoscopy: An International RAND/UCLA Appropriateness Study.
  Reena Khanna, Christopher Ma, Malcolm Hogan, Guangyong Zou, Talat Bessissow, Brian Bressler, Jean-Frédéric Colombel, Silvio Danese, Marco Daperno, James E East, Lawren...> ;Clinical Gastroenterology and Hepatology. 2023 Oct 1
• 2 citations
  Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study.
  Boyd Steere, Jochen Schmitz, Nick Powell, Richard Higgs, Klaus Gottlieb, Yushi Liu, Bochao Jia, Jay L Tuttle, William J Sandborn, Bruce E Sands, Geert D'Haens, Walter ...> ;Clinical and Translational Gastroenterology. 2023 Jul 1
• 1 citations
  The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn's Disease but Not Ulcerative Colitis Patients.
  Young Su Park, Sang Bum Kang, Ronald R Marchelletta, Harrison M Penrose, Roos Ruiter-Visser, Barbara Jung, Michael J Docherty, Brigid S Boland, William J Sandborn, Dec...> ;Pharmaceutics. 2023 Mar 2
• 29 citations
  Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
  William J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, Marla C Dubinsky, Julian Panes, Andres Yarur, Timothy Ritter, Filip Baert, Stefan Schreiber, Sheldon Sl...> ;Lancet. 2023 Apr 8
• 23 citations
  Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, contro...
  Brian G Feagan, Bruce E Sands, William J Sandborn, Matthew Germinaro, Marion Vetter, Jie Shao, Shihong Sheng, Jewel Johanns, Julián Panés> ;The Lancet. Gastroenterology & Hepatology. 2023 Apr 1
• 10 citations
  A tissue atlas of ulcerative colitis revealing evidence of sex-dependent differences in disease-driving inflammatory cell types and resistance to TNF inhibitor therapy.
  Aaron T Mayer, Derek R Holman, Anav Sood, Utkarsh Tandon, Salil S Bhate, Sunil Bodapati, Graham L Barlow, Jeff Chang, Sarah Black, Erica C Crenshaw, Alexander N Koron,...> ;Science Advances. 2023 Jan 20
• 15 citations
  Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study.
  William J Sandborn, Silvio Danese, Jaroslaw Leszczyszyn, Jacek Romatowski, Engin Altintas, Elena Peeva, Mina Hassan-Zahraee, Michael S Vincent, Padmalatha S Reddy, Chr...> ;Clinical Gastroenterology and Hepatology. 2023 Sep 1
• 6 citations
  High Discovery Rate of Duodenal and Gastric Eosinophilia in Patients With Unexplained Moderate-Severe Abdominal Symptoms: A Prospective US Multisite Study.
  Nicholas J Talley, Kathryn A Peterson, Robert M Genta, Alan T Chang, Evan S Dellon, William J Sandborn, , Brian E Lacy, Mirna Chehade, Ikuo Hirano, Nirmala Gonsalves, ...> ;Gastroenterology. 2023 Apr 1
• 7 citations
  Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.
  Siddharth Singh, Jihoon Kim, Jiyu Luo, Paulina Paul, Vivek Rudrapatna, Sunhee Park, Kai Zheng, Gaurav Syal, Christina Ha, Phillip Fleshner, Dermot McGovern, Jenny S Sa...> ;Clinical Gastroenterology and Hepatology. 2023 Aug 1
• 15 citations
  Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-bl...
  William J Sandborn, Julian Panés, Silvio Danese, Zaineb Sharafali, Azra Hassanali, Rhian Jacob-Moffatt, Christopher Eden, Marco Daperno, John F Valentine, David Lahari...> ;The Lancet. Gastroenterology & Hepatology. 2023 Jan 1
• 12 citations
  The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium.
  Amanda M Johnson, Maria Barsky, Waseem Ahmed, Samantha Zullow, Jonathan Galati, Vipul Jairath, Neeraj Narula, Farhad Peerani, Benjamin H Click, Elliot S Coburn, ThucNh...> ;The American Journal of Gastroenterology. 2023 Feb 1
• 7 citations
  Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease.
  Omoniyi J Adedokun, Zhenhua Xu, Christopher Gasink, Ken Kowalski, William J Sandborn, Brian Feagan> ;Clinical Therapeutics. 2022 Oct 1
• Join now to see all

Journal Articles

• Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium  
  Leah Katta, Robert Hirten, Shannon Chang, Dana Lukin, Edward V Loftus, David Faleck, Arun Swaminath, William J Sandborn, Sashidhar Varma Sagi, Sunanda Kane, Prianka Ch..., Nature
• Comparison of Multiplex Gastrointestinal Pathogen Panel and Conventional Stool Testing for Evaluation of Diarrhea in Patients with Inflammatory Bowel Diseases  
  Waseem Ahmad, Daniel Bouland, Nghia H Nguyen, David T Pride, Siddharth Singh, Parambir S Dulai, William J Sandborn, Brigid S Boland, Digestive Diseases and Sciences
• Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts  
  Parambir S Dulai, William J Sandborn, Brigid S Boland, Derek R Patel, Inflammatory Bowel Diseases
• Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report  
  Russell D Cohen, Uma Mahadevan, Bruce A Salzberg, Gary R Lichtenstein, William J Sandborn, Michael Safdi, Nature
• Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium  
  Gursimran Kochhar, Justin Hartke, Sashidhar Varma Sagi, Edward V Loftus, Joseph Meserve, Robert Hirten, David Faleck, Shannon Chang, Dana Lukin, Farhad Peerani, Leah K..., Nature
• No Benefit of Concomitant 5-Aminosalicylates in Patients with Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data from Cli...  
  Siddharth Singh, Parambir S Dulai, William J Sandborn, Nature
• Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials  
  Siddharth Singh, William J Sandborn, Nature
• Join now to see all